CINCINNATI, OH, USA (August 1, 2017) – M Pharmaceutical Inc. (CSE: MQ, OTCQB:MPHMF, FWB: T3F2) (“M Pharma”), announces today that to better align with its expertise in the healthcare field, it is changing the name and branding of its wholly owned subsidiary MPharmaceutical USA branding to Callitas Therapeutics Inc. The name of the parent company remains as it is for now.
A clinical-stage company developing innovative technologies for weight management and female health and wellness, the new name reflects its broader commitment to drive the innovations needed to shape the future of healthcare. The new corporate website is now – www.callitas.com.
“Our new name, Callitas Therapeutics, reflects our wide-ranging business objective of developing and delivering innovative technologies for weight management and female health and wellness,”said Gary Thompson, President and CEO of Callitas Therapeutics and M Pharma. “As a company with its roots in female health and wellness, we are committed to delivering breakthrough products and services that truly improve daily living. Aligning our logo with the beautiful and strong Calla Lily seems most appropriate in light of our mission.”
Formed in early 2015, Callitas Therapeutics Inc. is a clinical-stage company developing innovative technologies for obesity, weight management and female health & wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat and assets from 40J’sLLC, M Pharma is scheduled to launch their FDA cleared fertility product brandedas ToConceive sometime in September 2017.
M Pharmaceutical Inc. trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as“T3F2.”
For more information contact:
Callitas Investor Relations
Phone: +1 (859) 868-3131
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward looking statements. Although the Company believes that the expectations and assumptions on which the forward-CAN_DMS: \108136390\1looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward looking statements with respect to the regulatory approval, commercialization of the rights to the Company’s biomedical & drug technologies, and acquisition of new products. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile onwww.sedar.com and the Company’s filings to the CSE atwww.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices: C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.